Table 2.
Average weights (mean ± SD) and liver function tests of rats (n = 5) in the chronic phase after 7, 14, and 21 days of dosing.
| Group | Weight (g) | Liver function tests (units/L) | ||||
|---|---|---|---|---|---|---|
| (n = 5) | Before Rx | After Rx | Change | ALP | ALT | AST |
| Untreated | ||||||
| 7 days | 392 ± 13 | 404 ± 12 | 12 ± 4 | 262.5 ± 11 | 67.8 ± 24 | 169.3 ± 107 |
| 14 days | 399 ± 14 | 419 ± 21 | 21 ± 10 | 273.8 ± 57 | 55.4 ± 5 | 115.8 ± 10 |
| 21 days | 376 ± 24 | 397 ± 11 | 22 ± 4 | 285.0 ± 34 | 57.8 ± 6 | 120.8 ± 15 |
| (S + NVP) | ||||||
| 7 days | 264 ± 5 | 274 ± 11 | 10 ± 7 | 194.8 ± 31 | 58.5 ± 10 | 139.0 ± 58 |
| 14 days | 260 ± 8 | 278 ± 32 | 17 ± 24 | 208.7 ± 31 | 75.3 ± 6 | 126.0 ± 25 |
| 21 days | 279 ± 14 | 310 ± 4 | 31 ± 11 | 152.0 ± 64 | 49.0 ± 7 | 112.3 ± 12 |
| (LPS + NVP) | ||||||
| 7 days | 271 ± 5 | 256 ± 13 | −11 ± 9 | 403.3 ± 28 | 147.0 ± 13 | 427.0 ± 40 |
| 14 days | 269 ± 7 | 277 ± 8 | 8.0 ± 4 | 150.6 ± 11 | 52.0 ± 12 | 111.8 ± 26 |
| 21 days | 272 ± 9 | 295 ± 13 | 23 ± 9 | 165.0 ± 12 | 33.8 ± 7 | 89.8 ± 14 |
Key: Rx: treatment (Rx refers to test groups); S: saline; NVP: nevirapine; LPS: lipopolysaccharide; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase.